- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01345357
Study of CEP-9722 in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors or Mantle Cell Lymphoma
January 17, 2013 updated by: Cephalon
A Dose-Escalation Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of CEP-9722 (a PARP 1 and PARP 2 Inhibitor) in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors or Mantle Cell Lymphoma
The primary objective of the study is to determine the maximum tolerated dose (MTD) of CEP-9722 in combination with gemcitabine and cisplatin in patients with advanced solid tumors or mantle cell lymphoma.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
24
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Written informed consent is obtained. The patient has a either a histologically or cytologically confirmed malignant advanced solid tumor or a mantle cell lymphoma (and has experienced failure of as least 1 previous therapy) and the patient may benefit from the combination of gemcitabine and cisplatin.
- The patient has measurable or nonmeasurable disease evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 guidelines.
- The patient is a man or woman at least 18 years of age.
- The patient has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- The patient has a life expectancy of 12 weeks or more.
- The patient has adequate hematologic assessments and adequate renal and hepatic function as specified in the study protocol
- The patient has audiogram results without clinically significant abnormalities.
- The patient may have had chemotherapy provided that at least 3 weeks have elapsed and prior sequelae have resolved. If the patient has had prior radiation (curative or palliative) or prior treatment with nitrosoureas, a minimum of 4 weeks and 6 weeks, respectively, must have elapsed before treatment with CEP-9722.
- The patient has had no immunotherapy, including monoclonal antibody therapy, for at least 4 weeks and no hormonal therapy for at least 1 week, with the exception of patients with prostate cancer, who may continue hormonal therapy.
- Written informed consent is obtained.
- Agreement by women of childbearing potential (not surgically sterile or 2 years postmenopausal) to use a medically accepted method of contraception and continue the use of this method for the duration of the study and for 90 days after participation in the study. Acceptable methods of contraception include abstinence, barrier method with spermicide, intrauterine device (IUD), or steroidal contraceptive (oral, transdermal, implanted, and injected) in conjunction with a barrier method.
- Agreement by men not surgically sterile or who are capable of producing offspring to practice abstinence or use a barrier method of birth control, and continue use of this method for the duration of the study and for 6 months after participation in the study.
Exclusion Criteria:
- With the exception of cancer, the patient has any serious or uncontrolled surgical, medical, or psychiatric history that could prevent compliance with study procedures, or compromise the integrity of the study.
- The patient has any of the protocol specified risk factors for Torsade de Pointes
- The patient has a brain lesion requiring systemic therapy with corticosteroids or anti-convulsive agents.
- The patient has previous hypersensitivity reactions to 1 or more of the components of the CEP-9722, gemcitabine, or cisplatin drug products.
- The patient is a pregnant or breast-feeding woman. (Any women becoming pregnant during the study will be withdrawn from the study.)
- The patient is participating in another interventional clinical study at the time of enrollment or has participated in another interventional clinical study within 4 weeks prior to enrollment.
- The patient has any malabsorption syndrome and/or prior gastrectomy
- The patient has a concomitant uncontrolled and/or chronic infection or severe systemic disease.
- The patient has had previous treatment with another poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitor.
- The patient is unable to swallow tablets.
- The patient cannot interrupt continuous treatment with proton pump inhibitors and/or H2 receptor antagonists.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CEP-9722 in combination with Gemcitabine and Cisplatin
Study drugs will be administered in cycles of 21 days for up to 6 cycles.
CEP-9722 treatment will be initiated at cycle 2.
After cycle 3, patients may discontinue gemcitabine and/or cisplatin for reasons of tolerability, at the discretion of the investigator.
|
CEP-9722 will be administered orally from day 2 through day 7 of each cycle beginning with cycle 2.
The starting dose will be 150 mg twice daily.
Following cycle 2, the dose will either be decreased to 150 mg daily or increased to 200 mg twice daily in a cohort of 3 to 4 new patients.
Subsequent cycles will increase the dose by 100 mg twice daily in cohorts of 3 to 4 patients (with criteria to expand to 6 patients) to a maximum of 400 mg twice daily.
Patients must receive CEP-9722 to remain in the study.
Once treatment with CEP-9722 is discontinued, patients will withdraw from the study.
Gemcitabine will be administered at 1250 mg/m^2 intravenously on day 1 and day 8 of each 21-day cycle.
Dosage reduction may be applied on day 8 (within a cycle) or on day 1 of the next cycle based upon the grade of toxicity experienced by the patient.
Cisplatin will be administered at 75 mg/m^2 intravenously on day 1 of each cycle, after the infusion of gemcitabine.
Dosage reduction may be applied on day 1 of the next cycle based upon the grade of toxicity experienced by the patient.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Determination of the maximum tolerated dose (MTD) of CEP-9722 in combination with gemcitabine and cisplatin in patients with advanced solid tumors or mantle cell lymphoma.
Time Frame: Baseline and endpoint (as soon as possible after Day 21 of the last cycle)
|
To determine the maximum tolerated dose of CEP-9722, as defined by dose-limiting toxicities (DLTs) reported during the second 21-day treatment cycle (the first cycle of CEP-9722 administration).
|
Baseline and endpoint (as soon as possible after Day 21 of the last cycle)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluate the safety and tolerability of CEP-9722 in combination with gemcitabine and cisplatin
Time Frame: During the entire study, a minimum of 6 wks (two 21-day cycles) up to a maximum of 18 wks (six 21-day cycles).
|
Assessed by the occurrence of adverse events, clinical laboratory test results, vital signs measurements, electrocardiogram (ECG) findings, physical examination findings, and concomitant medication usage.
Creatinine clearance will be calculated according to the Cockroft-Gault formula.
An audiogram will be performed at screening and repeated during the study if clinically relevant according to the investigator.
Pts who complete or withdraw from treatment will have final procedures/assessments performed as soon as possible, after day 21 of the last cycle, at the end-of-treatment visit.
|
During the entire study, a minimum of 6 wks (two 21-day cycles) up to a maximum of 18 wks (six 21-day cycles).
|
Cmax pharmacokinetics parameter
Time Frame: Days 2 and 7 of Cycle 2 and Day 7 of Cycle 3
|
To characterize the pharmacokinetics profile of CEP-8983 (the active moiety of CEP-9722) following administration of CEP-9722, through measurement of the Maximum observed drug Concentration (Cmax).
|
Days 2 and 7 of Cycle 2 and Day 7 of Cycle 3
|
AUC pharmacokinetics parameter
Time Frame: Days 2 and 7 of Cycle 2 and Day 7 of Cycle 3
|
To characterize the pharmacokinetics profile of CEP-8983 (the active moiety of CEP-9722) following administration of CEP-9722, through measurement of the Area Under the plasma concentration-time Curve (AUC).
|
Days 2 and 7 of Cycle 2 and Day 7 of Cycle 3
|
Pharmacodynamics assessment
Time Frame: Screening and Day 2 of Cycle 2 at predose, and at 2 and 6 hours after administration of CEP-9722
|
To determine the extent of poly-adenosine diphosphate ribose polymerase (PARP) inhibition in peripheral blood mononuclear cells following administration of CEP-9722
|
Screening and Day 2 of Cycle 2 at predose, and at 2 and 6 hours after administration of CEP-9722
|
Efficacy - will be assessed by Tumor response evaluation of each patient
Time Frame: Screening, cycles 3 and 6, and every 2 cycles after cycle 6 until disease progression
|
Tumor response will be determined using the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 guidelines, when possible for patients with solid tumors.
For patients with mantle tumors, tumor response may be evaluated by the International Working Group criteria.
|
Screening, cycles 3 and 6, and every 2 cycles after cycle 6 until disease progression
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Sponsor's Medical Expert, MD, Cephalon, France
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2011
Primary Completion (Actual)
December 1, 2012
Study Completion (Actual)
January 1, 2013
Study Registration Dates
First Submitted
April 19, 2011
First Submitted That Met QC Criteria
April 28, 2011
First Posted (Estimate)
May 2, 2011
Study Record Updates
Last Update Posted (Estimate)
January 18, 2013
Last Update Submitted That Met QC Criteria
January 17, 2013
Last Verified
January 1, 2013
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma, Non-Hodgkin
- Lymphoma
- Lymphoma, Mantle-Cell
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Gemcitabine
Other Study ID Numbers
- C9722/1092
- 2010-023658-36 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Solid Tumors or Mantle Cell Lymphoma
-
Epizyme, Inc.CompletedFollicular Lymphoma | Marginal Zone Lymphoma | Advanced Solid Tumors | Mantle-Cell Lymphoma | Diffuse Large B Cell Lymphoma | Primary Mediastinal LymphomaUnited Kingdom
-
Northwestern UniversityBristol-Myers Squibb; National Cancer Institute (NCI); AbbVieUnknownUnresectable Solid Neoplasm | Recurrent Solid Neoplasm | Refractory Mantle Cell Lymphoma | Aggressive Non-Hodgkin Lymphoma | Advanced Solid Neoplasm | T-Cell Non-Hodgkin LymphomaUnited States
-
Korea Cancer Center HospitalUnknownRelapsed or Refractory Follicular Lymphoma or Mantle Cell LymphomaKorea, Republic of
-
Mirati Therapeutics Inc.TerminatedHodgkin Lymphoma | Non-Hodgkin Lymphoma (Follicular or Large Diffuse B-cell Lymphoma or Mantle Cell Lymphoma)United States
-
Northwestern UniversityNational Cancer Institute (NCI); Janssen Scientific Affairs, LLCActive, not recruitingStage III Mantle Cell Lymphoma | Stage IV Mantle Cell Lymphoma | Contiguous Stage II Mantle Cell Lymphoma | Noncontiguous Stage II Mantle Cell Lymphoma | Stage I Mantle Cell LymphomaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedRecurrent Mantle Cell Lymphoma | Stage III Mantle Cell Lymphoma | Stage IV Mantle Cell Lymphoma | Contiguous Stage II Mantle Cell Lymphoma | Noncontiguous Stage II Mantle Cell Lymphoma | Stage I Mantle Cell LymphomaUnited States
-
National Cancer Institute (NCI)CompletedStage III Mantle Cell Lymphoma | Stage IV Mantle Cell Lymphoma | Contiguous Stage II Mantle Cell Lymphoma | Noncontiguous Stage II Mantle Cell Lymphoma | Stage I Mantle Cell LymphomaUnited States
-
Janssen Biotech, Inc.Pharmacyclics LLC.Approved for marketingRelapsed or Refractory Mantle Cell LymphomaUnited States, Brazil, Puerto Rico
-
Roswell Park Cancer InstituteNational Comprehensive Cancer NetworkCompletedStage III Mantle Cell Lymphoma | Stage IV Mantle Cell Lymphoma | Stage I Mantle Cell Lymphoma | Stage II Contiguous Mantle Cell Lymphoma | Stage II Non-Contiguous Mantle Cell LymphomaUnited States
-
US Oncology ResearchEli Lilly and CompanyCompletedRelapsed or Refractory Mantle Cell Lymphoma (MCL)
Clinical Trials on CEP-9722
-
CephalonCompletedSolid TumorFrance, United Kingdom
-
Teva Branded Pharmaceutical Products R&D, Inc.Terminated
-
CephalonCompleted
-
CephalonCompletedPsoriasisUnited States
-
Teva Branded Pharmaceutical Products R&D, Inc.Completed
-
CephalonH. Lundbeck A/S; The Parkinson Study GroupTerminatedParkinson DiseaseUnited States, Canada, Puerto Rico
-
University of Michigan Rogel Cancer CenterRecruitingPancreatic Adenocarcinoma | Pancreatic Neuroendocrine Tumor | Pancreatic Neuroendocrine Carcinoma | Adenosquamous Carcinoma | Gastrointestinal Neuroendocrine Tumor | Gastrointestinal Neuroendocrine Carcinoma | Neuroendocrine Prostate CarcinomaUnited States
-
New Approaches to Neuroblastoma Therapy ConsortiumNational Cancer Institute (NCI)CompletedNeuroblastomaUnited States, Canada
-
Edwards LifesciencesCompletedCoronary Artery Disease | Heart Failure | Aortic Valve Stenosis | Aortic Valve Insufficiency | Aortic Valve DisorderCanada, United States, Austria, Germany, Spain, United Kingdom